See every side of every news story
Published loading...Updated

Pfizer's IXIFI Will Be Available In Canada As Of April - Canadian Manufacturing

Summary by Canadian Manufacturing
KIRKLAND — Pfizer Canada’s IXIFI (infliximab for injection) will be available in Canada as of April 1, 2025. IXIFI is a biosimilar to Remicade (infliximab). It was approved by Health Canada in December 2021 for all eligible indications of the reference product, including rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease (in adults and pediatric patients nine years and older), fistulising Crohn’s disease, ulcerative colitis (in adults…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Canadian Manufacturing broke the news in on Monday, March 17, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.